Zacks Investment Research
04 Aug 2026, 15:45 UTC · 1h ago
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
04 Aug 2026, 15:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Keros Therapeutics reported a Q2 2026 loss of $1.45 per share, which was wider than the Zacks Consensus Estimate of $1.25. — Missing earnings estimates typically triggers negative short-term price pressure.
-0.40Keros Therapeutics recorded zero revenues for the second quarter of 2026. — A total lack of revenue highlights the company's complete dependence on capital markets and clinical success.
-0.30The company expects its current cash resources of $257.6 million to fund operations into the first half of 2028. — Clear visibility on a multi-year cash runway reduces immediate bankruptcy or dilution risk.
+0.20Keros has initiated a phase II clinical study for rinvatercept in patients with Duchenne muscular dystrophy (DMD), with data expected in H1 2027. — Progress in the clinical pipeline is the primary driver of long-term value for biotech firms without products.
Continue reading
6 related stories
Top 2 movers · tap to explore
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
